Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (ABBV)
NYSE:ABBV
Holding ABBV?
Track your performance easily
ABBV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$135.85 - $190.97
Previous Close$189.71
Volume3.60M
Average Volume (3M)5.49M
Market Cap
$333.77B
Enterprise Value$390.97B
Total Cash (Recent Filing)$18.07B
Total Debt (Recent Filing)$74.00B
Price to Earnings (P/E)63.3
Beta0.30
Next Earnings
Oct 25, 2024EPS Estimate
$2.95Last Dividend Ex-Date
Jul 15, 2024Dividend Yield3.27%
Share Statistics
EPS (TTM)3.00
Shares Outstanding1,765,867,781
10 Day Avg. Volume5,765,939
30 Day Avg. Volume5,489,979
Standard Deviation0.07
R-Squared0.21
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-3.76
Price to Sales (P/S)6.03
Price to Cash Flow (P/CF)20.40
P/FCF Ratio18.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.19
Enterprise Value/Gross Profit11.53
Enterprise Value/Ebitda21.11
Forecast
1Y Price Target
$196.00Price Target Upside3.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
AbbVie News
Bulls Say, Bears Say
Bulls Say
AcquisitionsManagement commentary indicating that the announced Cerevel acquisition is on track for an imminent close helps allay a key uncertainty.
Financial PerformanceAbbVie reported EPS of $2.65, 3% above both consensus estimates and the high end of the guidance range.
Product PerformanceFactors underpinning growth for both Skyrizi and Rinvoq continue to propel upside.
Bears Say
Market CompetitionUnitedHealth/Optum Rx may be following CVS's and Cigna's biosimilar footsteps, eventually providing incremental pressure on Humira.
Regulatory ChallengesRegulatory challenges could pose risks to the company's future profitability.
Sales PerformanceAesthetics segment sales, including Botox Cosmetic and Juvederm, missed consensus estimates.
---
Ownership Overview
0.27% Insiders
22.63% Mutual Funds
23.79% Other Institutional Investors
53.31% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABBV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was $135.85 and its highest was $190.97 in the past 12 months.
What is AbbVie’s market cap?
Currently, no data Available
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Oct 25, 2024 which is in 84 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Jul 25, 2024. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.566 by $0.084.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $1.55 which represents an annual dividend yield of 3.27%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is $2.95.
How many shares outstanding does AbbVie have?
AbbVie has 1,765,867,800 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $2.65 in its last earnings report, beating expectations of $2.566. Following the earnings report the stock price went up 3.382%.
Which hedge fund is a major shareholder of AbbVie?
Among the largest hedge funds holding AbbVie’s share is Diamond Hill Capital Management Inc. It holds AbbVie’s shares valued at 245M.
---
AbbVie Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$196.00 (3.70% Upside)
$196.00 (3.70% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 95%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $49.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
ABBV Earnings Call
Q2 2024
0:00 / 0:00
---
ABBV Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
ABBV Stock 12 Month Forecast
Average Price Target
$196.00
▲(3.70% Upside)
Technical Analysis
Best Analysts Covering ABBV
1 Year
1 Year Success Rate
34/36 ratings generated profit
1 Year Average Return
+24.07%
reiterated a buy rating 11 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +24.07% per trade.
---